'Something NQR' - the understatement of the year. This management wholly backed a representative should be facing a trial . That says it all about their level of integrity with regards any future plans for the company. What happened with the push into the UK? Seems to me, if they even actually tried, the market is pushing back and refusing to endorse the test. Colostat is dead in the water thanks to them - dead.
- Forums
- ASX - By Stock
- Future Announcements
'Something NQR' - the understatement of the year. This...
Featured News
Add RHY (ASX) to my watchlist
|
|||||
Last
6.1¢ |
Change
0.001(1.67%) |
Mkt cap ! $15.16M |
Open | High | Low | Value | Volume |
6.1¢ | 6.1¢ | 6.1¢ | $366 | 6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 192904 | 6.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.6¢ | 80000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 192904 | 0.060 |
3 | 70988 | 0.059 |
2 | 25941 | 0.058 |
1 | 54545 | 0.055 |
2 | 79995 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.066 | 80000 | 1 |
0.070 | 76753 | 3 |
0.071 | 150525 | 1 |
0.072 | 2245 | 1 |
0.075 | 9200 | 1 |
Last trade - 13.49pm 03/07/2024 (20 minute delay) ? |
Featured News
RHY (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online